XTL Biopharmaceuticals Ltd. has announced an Extraordinary General Meeting of shareholders to be held on April 30, 2024, with key agenda items including the reelection of an external director, the approval of option grants to various board members, and the ratification of a new clawback policy. Additionally, the meeting will cover the approval of a $1.5 million private placement contingent on acquiring The Social Proxy Ltd. Shareholders as of March 28, 2024, are invited to vote in person or via proxy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.